Semler Scientific (SMLR) has received a new Buy rating, initiated by Benchmark Co. analyst, Mark Palmer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mark Palmer has given his Buy rating due to a combination of factors influencing Semler Scientific’s strategic direction and market potential. The company’s recent pivot from a healthcare-focused business to adopting Bitcoin as its primary treasury reserve asset has been a significant driver of its stock appreciation. Despite this strategic shift, Semler Scientific’s valuation still lags behind its peers, presenting an opportunity for growth as it seeks to narrow the gap.
Furthermore, the company’s ambitious goals for expanding its Bitcoin treasury, alongside the appointment of a Director of Bitcoin Strategy, underscore its commitment to enhancing execution and investor engagement. Additionally, resolving challenges in its legacy healthcare business, such as the DOJ investigation and Medicare reimbursement issues, could further bolster its valuation. Mark Palmer’s price target of $101 reflects a sum-of-the-parts analysis, considering both the potential appreciation of Bitcoin and the value of Semler Scientific’s healthcare operations.